NYSE$LLY

Eli Lilly & Co · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Lilly experienced growth and pipeline success, driven by volume and key growth products, despite pandemic-related challenges.

Eli Lilly reported an 8% increase in revenue for Q4 2021, driven by an 11% increase in volume. Excluding COVID-19 antibodies, revenue grew by 6%. EPS decreased by 18% to $1.90 on a reported basis but increased by 8% to $2.49 on a non-GAAP basis. The company reaffirmed its 2022 EPS guidance.

  • Revenue in Q4 2021 increased 8 percent, driven by volume growth of 11 percent.
  • Excluding COVID-19 antibodies, fourth-quarter 2021 revenue grew 6 percent.
  • Key growth products contributed 14 percentage points of revenue growth and represented 61 percent of total revenue in Q4 2021, excluding revenue from COVID-19 antibodies.
  • Fourth-quarter 2021 EPS decreased 18 percent to $1.90 on a reported basis and increased 8 percent to $2.49 on a non-GAAP basis.

Headline financials

Total Revenue

$8B

Previous: $7.44B+7.5%
EPS (adj)

$2.49

Previous: $2.75-9.5%
Net Income

$1.73B

Previous: $2.12B-18.5%
Operating Income

$1.92B

Previous: $1.99B-3.8%
Gross Profit

$5.95B

Previous: $5.72B+4.0%
Cash & Equivalents

$3.82B

Previous: $3.66B+4.4%
Total Assets

$48.8B

Previous: $46.6B+4.7%
Stock-Based Comp

$75.3M

Previous: $87.8M-14.2%

Revenue & EPS history

Eli Lilly · Revenue · Quarterly

$8B

Q4 2021+7.5%vs Q4 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Eli Lilly · $2.45B total across 2 segments · Q3 2023

  • Mounjaro
    $1.41B+652.4%
  • Verzenio
    $1.04B+68.4%

Forward guidance

The company has reaffirmed all elements of its 2022 financial guidance. EPS for 2022 are still expected to be in the range of $8.00 to $8.15 on a reported basis and $8.50 to $8.65 on a non-GAAP basis.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

+0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+3.1%

Avg return

30 days after

43%

29 / 67 earnings

Positive

+15.9%

Q2 2023

Best reaction

-14.1%

Q2 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.1%+16.2%+29.9%
Q4 2025+10.3%+4.1%-1.3%
Q3 2025+3.2%+11.5%+32.2%
Q2 2025-14.1%-14.3%-2.6%
Q1 2025-11.7%-13.8%-17.9%
Q4 2024+3.3%+2.7%+3.3%
Q3 2024-8.2%-10.8%-12.0%
Q2 2024+15.5%+17.6%+16.9%
Q1 2024+5.4%-0.3%+10.6%
Q4 2023+2.7%+4.8%+10.5%
Q3 2023+2.4%+8.2%+5.3%
Q2 2023+15.9%+16.3%+26.2%
Q1 2023+5.2%+7.4%+13.2%
Q4 2022-1.0%-0.8%-7.0%
Q3 2022-2.0%-1.3%+2.3%
Q2 2022-4.0%-3.4%-4.0%
Q1 2022+2.5%+1.0%+13.5%
Q4 2021-3.4%-4.4%+4.8%
Q3 2021+2.1%+4.0%+6.9%
Q2 2021+6.4%+6.8%+5.3%
Q1 2021-3.6%-2.4%+6.4%
Q4 2020-3.3%-6.3%-2.5%
Q3 2020-7.3%-7.9%+2.2%
Q2 2020-7.1%-4.3%-8.9%
Q1 2020+4.0%+0.4%-3.5%
Q4 2019-0.2%+2.5%-9.9%
Q3 2019-1.8%+2.9%+5.8%
Q2 2019+0.2%+3.4%+3.2%
Q1 2019-1.2%-2.2%-3.1%
Q4 2018-2.4%-2.0%+5.2%
Q3 2018-0.4%+1.9%+5.2%
Q2 2018+8.5%+8.7%+17.9%
Q1 2018+1.2%+3.2%+3.1%
Q4 2017-4.3%-10.0%-10.3%
Q3 2017-2.7%-3.8%-4.0%
Q2 2017-3.4%-1.9%-6.9%
Q1 2017-2.9%-1.6%-6.1%
Q4 2016+3.9%+3.4%+11.0%
Q3 2016-1.0%-3.9%-12.3%
Q2 2016+1.7%+1.1%-4.8%
Q1 2016-1.8%
Q4 2015-3.3%
Q3 2015+1.7%
Q2 2015-1.9%
Q1 2015-1.0%
Q4 2014-0.6%
Q3 2014+2.1%
Q2 2014-0.7%
Q1 2014-1.8%
Q4 2013+0.2%
Q3 2013+0.8%
Q2 2013+3.1%
Q1 2013-3.3%
Q4 2012+2.9%
Q3 2012-1.6%
Q2 2012+3.9%
Q1 2012+2.3%
Q4 2011+1.0%
Q3 2011-1.9%
Q2 2011-0.1%
Q1 2011-0.1%
Q4 2010-1.6%
Q3 2010-0.3%
Q2 2010+2.5%
Q1 2010+0.4%
Q4 2009-0.8%
Q4 2008-0.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro